Glenmark Pharmaceuticals has introduced the antiviral drug favipirvir under the brand name Fabiflu to treat patients with mild to moderate and moderate suffering from Kovid-19. The company gave this information on Saturday. The Mumbai-based company said on Friday that it had received permission from the Controller General of India (DGCI) to manufacture and market the drug. The company said that Fabiflu is the first food favipirvir drug to treat Kovid-19, which has been approved. This drug will be available in the market at the rate of around Rs 103 per tablet.
Glenmark Pharmaceuticals said the drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets. Glenn Saldanha, chairman and managing director of Glamark Pharmaceuticals, said the approval has come at a time when the corona virus cases in India are increasing more rapidly than before. This has put our healthcare system under great pressure. He hoped that the availability of effective treatment like Fabiflu would help reduce this pressure to a great extent.
Fabiflu is the first oral favipirvir approved drug in India for the treatment of Kovid-19. It has been recommended for 1,800 mg twice in the first day and 800 mg twice daily for 14 days thereafter. The tablet is being produced by the company in Baddi, Himachal Pradesh. Glenmark said the drug would be available through both hospitals and retail channels. Glenmark said the company has successfully developed active pharmaceutical ingredients (APIs) and formulations for Fabiflu through its in-house research and development team.